Humira (adalimumab) remains one of the most prescribed biologic medications, but the landscape has shifted dramatically with the arrival of multiple biosimilars in 2023 and 2024. Most insurance plans now prefer biosimilar adalimumab products over brand-name Humira, offering lower copays for biosimilars. Patients on Humira may face step therapy requirements to switch to a biosimilar.
Key Facts
Check Your Specific Plan's Formulary
Coverage varies by plan. Use our formulary checker tool to look up your exact copay and restrictions.
Open Formulary CheckerSources and standards behind this page
Drug coverage in the United States is governed by published rules rather than by any one insurer's summary, and the sources below are the primary ones. They are linked so a reader can check a claim without taking this page's word for it.
- FDA Orange Book publishes the therapeutic-equivalence ratings that decide whether a generic may be substituted for a brand-name drug.
- FDA generic drug facts sets out what "generic equivalent" means and what a manufacturer must prove.
- CMS prescription drug coverage defines the rules a Medicare drug plan formulary must follow and how it may change mid-year.
- Medicare.gov drug coverage (Part D) states what a Part D plan is required to offer a member.
- CMS prescription drug appeals documents the coverage-determination and exception process when a drug is denied.
This page describes how coverage and formularies work. It is not medical advice, and a reader's own plan documents and prescriber decide what applies to them.
Frequently Asked Questions
Many insurance plans are now requiring or incentivizing switches to biosimilar adalimumab products. Some plans have moved brand Humira to a non-preferred tier with higher copays. Your doctor can request a formulary exception if there is a clinical reason to stay on brand Humira. Check with your insurer for your plan's specific policy.
Yes. FDA-approved biosimilars must demonstrate no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Clinical studies for each biosimilar confirmed equivalent efficacy. The FDA's rigorous approval process ensures biosimilars are safe and effective alternatives.
With insurance, Humira copays range from $5 (with manufacturer copay card) to $500+ per month depending on your plan and tier. Biosimilar copays are typically $0 to $50 on preferred tiers. AbbVie's copay assistance program covers up to $16,000/year in out-of-pocket costs for commercially insured patients.
Related Resources
- UnitedHealthcare Formulary 2026
- Aetna Formulary 2026
- Cigna Formulary 2026
- Dupixent cash price comparison on RxGrab
- Rinvoq cash price comparison on RxGrab
- Skyrizi cash price comparison on RxGrab
- Enbrel cash price comparison on RxGrab
- Stelara cash price comparison on RxGrab
- Dupixent patient assistance program
- Rinvoq patient assistance program
- Skyrizi patient assistance program
- Drug interaction checker tool
- Patient assistance program finder
Get Formulary and Coverage Updates
Subscribe to receive alerts on formulary changes, new drug approvals, and insurance coverage updates.